Passage Bio, Inc. (PASG) Insider Trading Activity

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Show less

Over the last 12 months, insiders at Passage Bio, Inc. have bought $525,558 and sold $1.02M worth of Passage Bio, Inc. stock.

On average, over the past 5 years, insiders at Passage Bio, Inc. have bought $1.01M and sold $456,650 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lynx1 Capital Management LP (10 percent owner) — $525,558.

The last purchase of 373,645 shares for transaction amount of $241,038 was made by Lynx1 Capital Management LP (10 percent owner) on 2024‑12‑27.